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Abstract
Objective: To compare patients with cystic fibrosis and healthy individuals in terms of their functional performance 
on the six-minute walk test (6MWT). Methods: A prospective, cross-sectional study involving healthy individuals 
and patients with cystic fibrosis treated at a referral university hospital in the city of Campinas, Brazil. The 6MWT 
was administered in accordance with the American Thoracic Society guidelines, and it was repeated after a 30-min 
rest period. For all of the participants, RR, HR, SpO2, and Borg scale scores were obtained. For the cystic fibrosis 
patients, nutritional status and spirometric values were determined. Patients with pulmonary exacerbation were 
excluded. Spearman’s correlation coefficient and repeated measures ANOVA were used. Results: The cystic fibrosis 
group comprised 55 patients, and the control group comprised 185 healthy individuals. The mean ages were 
12.2 ± 4.3 and 11.3 ± 4.3 years, respectively. The six-minute walk distance (6MWD) was significantly shorter in the 
cystic fibrosis group than in the control group for both tests (547.2 ± 80.6 m vs. 610.3 ± 53.4 m for the first and 
552.2 ± 82.1 m vs. 616.2 ± 58.0 m for the second; p < 0.0001 for both). The 6MWD correlated with age, weight, 
and height only in the cystic fibrosis group. During the tests, SpO2 remained stable, whereas HR and RR increased. 
Conclusions: In our sample, functional performance on the 6MWT was poorer among the cystic fibrosis patients 
than among the healthy controls in the same age bracket, and we found immediate repetition of the test to be 
unadvisable. 
Keywords: Cystic fibrosis; Exercise tolerance; Dyspnea.
Resumo
Objetivo: Comparar pacientes com fibrose cística e indivíduos saudáveis quanto ao desempenho funcional no teste 
de caminhada de seis minutos (TC6). Métodos: Estudo transversal e prospectivo, com indivíduos saudáveis e com 
fibrose cística de um hospital universitário de referência na cidade de Campinas (SP). O TC6 foi aplicado de acordo 
com as normas da American Thoracic Society e repetido após 30 min de repouso. Foram determinados FR, FC, SpO2 
e escore da escala de Borg em todos os participantes, assim como o status nutricional e valores espirométricos para 
os pacientes com fibrose cística. Excluíram-se pacientes em exacerbação pulmonar. Foram utilizados coeficientes 
de correlação de Spearman e ANOVA para medidas repetidas. Resultados: Foram incluídos 55 pacientes no grupo 
fibrose cística e 185 indivíduos saudáveis no grupo controle, com médias de idade de 12,2 ± 4,3 anos e 11,3 ± 
4,3 anos, respectivamente. A distância percorrida no TC6 (DTC6) foi significativamente menor no grupo fibrose 
cística que no grupo controle em ambos os testes (547,2 ± 80,6 m vs. 610,3 ± 53,4 m no primeiro e 552,2 ± 
82,1 m vs. 616,2 ± 58,0 m no segundo; p < 0,0001 para ambos). A DTC6 se correlacionou com idade, peso e 
altura somente no grupo fibrose cística. A SpO2 manteve-se estável durante o teste, com aumento da FC e da FR. 
Conclusões: Nesta amostra, os pacientes com fibrose cística apresentaram um menor desempenho funcional no 
TC6 quando comparados a indivíduos saudáveis de mesma faixa etária, sem a necessidade de repetição imediata 
do teste.
Descritores: Fibrose cística; Tolerância ao exercício; Dispneia.
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However, those studies lack consistency in 
terms of sample size and ethnic variability. The 
objective of the present study was to compare 
cystic fibrosis patients with healthy individuals 
in terms of their performance on the 6MWT, 
as assessed by the six-minute walk distance 
(6MWD).
Methods
This was a prospective, cross-sectional study 
carried out between March of 2009 and March 
of 2010 and involving a nonrandom sample of 
patients treated at the University Hospital of the 
Faculdade de Ciências Médicas da Universidade 
Estadual de Campinas (FCM-Unicamp, State 
University at Campinas School of Medical 
Sciences), located in the city of Campinas, Brazil. 
The study was approved by the FCM-Unicamp 
Research Ethics Committee (Protocol no. 
504/2008). All of the participants or their legal 
guardians gave written informed consent.
The sample size was planned to accommodate 
a ratio of at least two controls per case of 
cystic fibrosis. All patients between 6 and 25 
years of age who were under treatment at the 
cystic fibrosis outpatient clinic of the university 
hospital were invited to participate in the study. 
The cystic fibrosis (CF group) comprised patients 
in whom the diagnosis of cystic fibrosis had been 
confirmed by two abnormal sweat test results 
(chloride > 60 mEq/L) or by the presence of two 
confirmed mutations in the gene that encodes 
the cystic fibrosis transmembrane conductance 
regulator protein.
To identify pulmonary exacerbations and 
assess the severity of cystic fibrosis, we used 
the cystic fibrosis clinical score, the Cystic 
Fibrosis Foundation score, and the Shwachman-
Kulczycki score.(9) Patients with acute pulmonary 
exacerbation, as identified by the scores (cystic 
fibrosis clinical score > 25 and  Cystic Fibrosis 
Foundation score ≥ 4), were excluded from 
the study, as were those who were oxygen-
dependent and those who failed to return to the 
outpatient clinic during the collection period.
The control group consisted of students 
attending a public elementary school, as well as 
of healthy health professionals and volunteers 
who agreed to participate in the study. Ages 
ranged from 6 to 25 years. Individuals with a 
history of respiratory disease were excluded, as 
Introduction
The six-minute walk test (6MWT) is a 
submaximal, self-paced exercise tolerance test 
that is easy to administer and well tolerated. 
The 6MWT is reflective of activities of daily 
living and evaluates the global and integrated 
responses of all the systems involved during 
exercise: pulmonary and cardiovascular 
systems; peripheral and systemic circulation; 
neuromuscular units; and muscle metabolism.(1)
The 6MWT is used for assessing results 
before and after treatment of patients with 
moderate or severe pulmonary heart disease 
and for assessing cardiopulmonary status, as 
well as being used in epidemiological studies. 
The 6MWT is an inexpensive tool, is easily 
reproducible in outpatient settings, and yields 
sufficiently reliable results.(2)
The use of the 6MWT by numerous health 
care facilities worldwide has raised interest in 
standardizing the test. Some authors(3,4) have 
denounced a lack of standardization, in children 
and adults, as a negative aspect of the choice 
of the test as a research tool. There have been 
advances in the standardization and use of the 
6MWT in scientific investigations in adults.(1,2)
Cystic fibrosis is a severe autosomal recessive 
hereditary disease, with variability in symptom 
onset and presentation. Its incidence varies 
according to ethnicity. In Brazil, the incidence 
of cystic fibrosis is estimated at 1/10,000 live 
births.(5)
The clinical triad that characterizes the 
disease consists of progressive, chronic, 
suppurative, obstructive pulmonary disease, 
pancreatic insufficiency (causing poor digestion 
and poor nutrient absorption), and abnormally 
high concentrations of sweat electrolytes.(5) 
Although the mechanisms of physical activity 
intolerance remain unclear, children and 
adolescents with cystic fibrosis appear to have 
a favorable therapeutic response to physical 
activity, including an improved prognosis. 
Favorable prognosis is associated with better 
aerobic conditioning and better nutritional 
status. In most patients, death results from a 
decline in pulmonary function.(6)
Various studies have administered the 6MWT 
to patients with cystic fibrosis (Chart 1), with 
different purposes. Recent studies(7,8) have 
attempted to establish reference values for the 
6MWT in healthy children and adolescents. 
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was administered to one individual at a time. 
It was explained to participants that, during 
the test, they could stop walking at any time if 
they experienced discomfort, but that test time 
would continue to be counted.(1)
Statistical analyses were performed with the 
SAS System software for Windows, version 9.2 
(SAS Institute, Cary, NC, USA). Data are presented 
as mean ± SD. The Mann-Whitney test was 
employed to compare the two groups. We used 
repeated measures ANOVA on rank-transformed 
data in order to evaluate differences among tests 
over time. Spearman’s correlation coefficient was 
employed to assess linear correlation between 
variables. Multiple linear regression analysis was 
used for the identification of factors affecting 
the 6MWT, whereas the intraclass correlation 
coefficient and Bland & Altman plots were used 
for the assessment of reproducibility.(13) The 
greatest 6MWD achieved by each participant 
was chosen for analyses. The level of significance 
was set at 5%.
Results
In 2009, 168 patients were being treated at 
the cystic fibrosis outpatient clinic. Of those, 
96 were considered eligible, in terms of age, to 
participate in the study. Of those 96, 41 were 
excluded for the following reasons: declining 
to participate in the study (n = 15); having 
pulmonary exacerbation (n = 12); missing 
physician visits (n = 10); and being on continuous 
oxygen therapy (n = 4). Therefore, the CF group 
comprised 55 patients, and the control group 
comprised 185 healthy individuals. The mean 
ages were 12.2 ± 4.3 years and 11.3 ± 4.3 years, 
respectively (overall range, 6.0-24.9 years).
The groups were found to be homogeneous 
in terms of their distributions by age, weight, 
height, and gender (Table 1). There were 
differences in terms of BMI and nutritional status. 
The percentage of malnourished individuals was 
higher in the CF group than in the control group 
(25.45% vs. 8.11%; p = 0.0016).
In the CF group, the mean Shwachman-
Kulczycki score was 75.29 ± 10.11 (range, 
50-90), clinical status being classified as 
follows: excellent, in 4; good, in 29; mild, in 
14; and moderate, in 4. None of the patients 
were classified as having severe disease. The 
calculation of the Shwachman-Kulczycki score 
were those with orthopedic impairments and 
those who were smokers. 
Anthropometric measurements (weight 
and height) were taken, and body mass index 
(BMI, kg/m²) was calculated, the latter classified 
in accordance with the Centers for Disease 
Control reference values, by gender and age.(10) 
All measurements were performed by standard 
measurement techniques.
Only the CF group underwent spirometry, 
which was performed in the Pulmonary Function 
Laboratory of the FCM-Unicamp Center for 
Pediatric Research. To that end, a CPFS/D 
spirometer (Medical Graphics Co., Saint Paul, 
MN, USA) and Breeze PF software, version 3.8B 
(Medical Graphics Co.), were used, in accordance 
with the guidelines of the European Respiratory 
Society and the American Thoracic Society. The 
predicted values of the following spirometric 
variables were studied: FVC; FEV1; and FEF25-75%, 
with the use of the reference values proposed 
by Polgar & Promadhat.(11) For the CF group 
patients whose test had been performed up to 
3 months before the 6MWT, data were obtained 
retrospectively. All other CF group patients were 
referred for a second test.
The 6MWT was performed identically in both 
groups. A 30-m indoor course was delineated 
with cones, which were arranged in a straight 
line, 3 m apart, on level ground. While the 
patient remained seated, RR, HR, and SpO2 
were measured, the last with a portable pulse 
oximeter (Oximed Plus®; Oximed, Porto Alegre, 
Brazil), and modified Borg scale scores were 
obtained.(1)
Each participant was instructed to complete 
as many laps as possible in 6 min, walking 
briskly, but without running or jogging. At the 
end of every minute, the patient was informed 
of how many minutes remained and was given 
verbal encouragement in a neutral tone of voice 
(“You’re doing well” and “Keep up the good 
work”). The investigator stood at one end of the 
walking course holding a stopwatch.(1)
After 6 min, the patient was instructed to 
stop. The distance from the cone to the spot 
where the patient stopped was then measured. 
While the individual remained seated, HR, 
RR, SpO2, and Borg scale scores
(1) were again 
obtained, immediately after the test and after a 
3-min rest period. After a 30-min rest period,(12) 
a second 6MWT was administered. Each test 
Functional performance on the six-minute walk test in patients with cystic fibrosis
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Spearman’s linear correlation test revealed 
that the 6MWD correlated moderately with 
height, weight, and age in the CF group. In the 
control group, the 6MWD did not correlate with 
any of the variables studied.
Stepwise multiple linear regression was used 
for the selection of the variables that most 
affected the 6MWD in the CF group. Weight 
(p = 0.0263), height (p = 0.0007), and FEV1 
(% of predicted; p = 0.0017) were responsible 
for 45.5% of the behavior of the dependent 
variable (R2 = 0.4550). The formula developed 
to predict the 6MWD, only for the CF group, 
was as follows: 
6MWD = −257 − [5.4 × weight (kg)] + 
[628.03 × height (m)] + [164 × FEV1 (% of 
predicted)]
It was not possible to develop a formula to 
predict the 6MWD for the control group because 
of the lack of correlation between the 6MWD 
and the variables studied.
In the first and second 6MWTs, the 
cardiorespiratory variables of the groups were 
measured at three different time points: at rest; 
at the sixth minute of the 6MWT; and at three 
minutes after completion of the 6MWT, i.e., at 
the ninth minute.
In the control group, RR (Figure 2a) increased 
significantly in the second 6MWT, at two 
different time points: at rest (18.6 ± 4.0 breaths/
could not be completed in 4 patients because of 
the lack of a recent chest X-ray.
The mean percentage of predicted FEV1 was 
77.33% ± 21.90% (range, 38%-132%), whereas 
the mean percentage of predicted FVC was 
85.56 ± 18.95% (range, 52-131%) and the mean 
percentage of predicted FEF25-75% was 64.17 ± 
32.84% (range, 14-138%).
All of the participants completed the 6MWT 
without stopping. The 6MWD was shorter in the 
CF group than in the control group for the first 
test (547.2 ± 80.6 m vs. 610.3 ± 53.4 m; p < 
0.001) and for the second test (552.2 ± 82.1 
m vs. 616.2 ± 58.0 m; p < 0.0001). There were 
no differences between the mean 6MWD for the 
first and second tests in either of the two groups 
(p = 0.0625).
The 6MWD was not found to be affected by 
gender (p = 0.1586 and p = 0.7753 for the CF 
group and the control group, respectively) or 
genetic mutations (p = 0.8892 for the CF group).
The reproducibility of the 6MWT, as assessed 
by the intraclass correlation coefficient, showed 
concordance of 0.810 (95% CI: 0.696-0.885) 
and 0.770 (95% CI: 0.704-0.823) in the CF 
group and the control group, respectively. The 
Bland & Altman plots (Figure 1) show that the 
tests were very close and indicate the reliability 
of the measurements.
Table 1 - Age and gender distribution, as well as distribution of weight, height, BMI, and six-minute walk 
distance values, by study group.
Variable Group n Mean ± SD Minimum Median Maximum p
Age, years CF 55 12.2 ± 4.3 6.1 11.1 23.3 0.0962*
CG 185 11.3 ± 4.3 6 10.2 24.9
Weight, kg CF 55 37.3 ± 15.5 18.2 35 79 0.0960*
CG 185 41.6 ± 18.0 18.0 37.2 105
Height, m CF 55 1.04 ± 0.20 1.1 1.4 1.8 0.3967*
CG 185 1.5 ± 0.2 1.1 1.4 1.9
BMI, kg/m² CF 55 17.4 ± 3.1 11.9 17.1 27.3 0.05*
CG 185 18.6 ± 4.0 12 18 33.3
6MWD 1st test, m CF 55 547.2 ± 80.6 390.6 540.0 768.0  
CG 185 610.3 ± 53.4 420.00 612.0 739.0
6MWD 2nd test, m CF 55 552.2 ± 82.1 374.4 554.0 772.8 0.0625***
CG 185 616.2 ± 58.0 450.0 618.0 771.0
Gender Male Female  
CF 55 40.00% 60.00% 0.6692**
CG 185 43.24% 56.76%
CF: cystic fibrosis; CG: control group; BMI: body mass index; and 6MWD: six-minute walk-distance. *Nonparametric 
Mann-Whitney test. **Chi-square test. ***Value of p for the purpose of the test. Repeated measures ANOVA on rank-
transformed data.
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assessed in both tests (p < 0.0001), which 
suggests that the 6MWT caused significant 
changes in HR of participants.
In the CF group, the greatest HR was 
observed in the first 6MWT. The variation in HR 
among the three different time points assessed 
(i.e., at rest, at the sixth minute, and at the ninth 
minute) was statistically significant (p < 0.0001). 
In the second 6MWT, there was no difference 
in HR between the first and third time points 
assessed (i.e., at rest and at the ninth minute; 
p = 0.2798), which suggests a return to values 
close to baseline.
In the control group, SpO2 (Figure 3a) showed 
a statistically significant reduction in the second 
6MWT only at the sixth minute, decreasing 
from 98.2 ± 1.0% to 97.9 ± 1.0% (p = 0.0002). 
Although 1 patient in the CF group showed 
SpO2 values ranging from 82% to 100%, SpO2 
remained stable throughout the three different 
time points assessed in the two 6MWTs in the 
CF group.
In the control group, there were statistically 
significant differences in dyspnea levels, as 
measured by the modified Borg scale (Figure 3b), 
at all time points assessed in both tests. In the 
CF group, there were differences between the 
two 6MWTs, dyspnea levels being higher in the 
first 6MWT.
Discussion
The search for inexpensive, user-friendly tools 
for the assessment and monitoring of chronic 
pulmonary diseases is a recent concern in the 
international literature. In our study, the 6MWD 
min vs. 19.6 ± 4.4 breaths/min; p = 0.0012) and 
at the sixth minute (27.0 ± 7.0 breaths/min vs. 
28.0 ± 6.8 breaths/min; p = 0.0164). In the CF 
group, RR increased considerably between rest 
and the sixth minute (p < 0.0001) in both tests, 
demonstrating the effort put forth by patients 
during physical exercise.
In the control group, HR (Figure 2b) was 
found to be higher in the second 6MWT (p < 
0.0001), being different at all time points 
a
b
Figure 1 - Bland & Altman plots for the cystic fibrosis 
group (in a) and the control group (in b).
ba
Figure 2 - Behavior of the variables RR (in a) and HR (in b) in the cystic fibrosis and control groups. 6MWT 1: 
first six-minute walk test; and 6MWT 2: second 6MWT.
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in that the 6MWD was significantly shorter in 
the CF group than in the control group (675 ± 
66 m vs. 808 ± 105 m; p < 0.05). Another group 
of authors,(19) who also administered the 6MWT 
to adults with cystic fibrosis (n = 64; mean age: 
26 ± 8 years; and mean FEV1 [% of predicted] 
= 65 ± 19%), reported differences between the 
CF group and the control group (702 ± 82 m vs. 
833 ± 93 m; p < 0.0001).
Cunha et al.(12) administered the 6MWT to 
16 children with cystic fibrosis and with poorer 
nutritional and pulmonary status than that 
of those in our sample (mean FEV1 and mean 
BMI of 63.1 ± 21.1% and 15.8 ± 2.4 kg/m2, 
respectively). Nevertheless, they reported greater 
6MWDs than those achieved in our study: 582.3 
± 60.0 m and 598.2 ± 56.8 m for the first and 
second tests, respectively. However, the small 
number of participants should be considered as 
a limitation of that study.
Factors limiting exercise capacity in cystic 
fibrosis patients are well described in the 
literature and include reduced pulmonary 
function, malnutrition, and muscle weakness. 
Other factors are higher RR with lower tidal 
volume, hypoxemia, and poor ventilation.(20-22)
In a study involving 188 healthy children 
between 6 and 12 years of age, the mean 6MWD 
was shorter than that achieved by our control 
group for the first 6MWT (579.4 ± 68.1 m vs. 
610.3 ± 53.4 m) and the second 6MWT (569.2 
± 83.4 m vs. 616.2 ± 58.0 m).(8) However, our 
study included adolescents and young adults, 
with different anthropometric characteristics.
was shorter among the individuals with cystic 
fibrosis than among the healthy individuals. To 
date, there have been only six studies comparing 
cystic fibrosis patients and controls in terms of 
their performance on the 6MWT; only three of 
those studies have reported mean ages close to 
those of our sample.
In 2000, with the aim of testing a new 
assessment tool for dyspnea (the fifteen-count 
breathlessness score), Prasad et al.(14) evaluated 
55 children with cystic fibrosis and 33 healthy 
children (range, 6-8 years) by using the 6MWT 
and the step test. However, the authors did not 
analyze the distances covered. Lesser et al.(15) 
administered the 6MWT to healthy individuals 
and cystic fibrosis patients (mean age: 14.3 ± 3.8 
years). The 6MWD was shorter among the cystic 
fibrosis patients than among the controls (468 
± 68 m vs. 557 ± 73 m, respectively; p < 0.05). 
Gruber et al.(16) tested the effects of a physical 
fitness training program in 286 cystic fibrosis 
patients and 44,000 healthy children (mean age: 
11.8 ± 3.4; range, 6-18 years). The 6MWT was 
used for assessing aerobic capacity at the end 
of the fourth and sixth months of training: the 
6MWD increased by 4.4% in the CF group (p < 
0.05). In that study, the 6MWD was shorter in 
the CF group than in the control group at the 
beginning and end of the training program (p 
< 0.05, for both measurements). Chetta et al.(17) 
studied 47 adult patients and reported similar 
performances in the CF group and the control 
group (626 ± 49 m and 652 ± 46 m, respectively). 
Despite including adults, a study by Gruet et al.
(18) reported results that corroborate our findings 
a b
Figure 3 - Behavior of the variables SpO2 (in a) and dyspnea as assessed by the modified Borg scale score (in 
b) in the cystic fibrosis and control groups. 6MWT 1: first six-minute walk test; and 6MWT 2: second 6MWT.
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Although the equations proposed by Li et al.
(7) and Geiger et al.(27) are innovative, they have 
an ethnic-specific configuration, and this can 
make it difficult to adopt them as reference 
equations in Brazil. The study by Priesnitz et al.
(8) is certainly the closest to ours in terms of the 
make-up of the study population. We suggest 
that the equation devised by Priesnitz et al. be 
used in research centers throughout Brazil in 
order to determine whether there is concordance 
between the results obtained in the 6MWTs and 
the values predicted by the equation.
Few studies have included percentage of 
predicted FEV1 in their equations to predict 
6MWD. The use of spirometric values in the 
reference equation is important for cystic fibrosis 
patients, because the degree of pulmonary 
impairment in each individual is taken into 
account, which translates to the distance 
predicted by the equation being closer to the 
actual distance covered by the patient with 
pulmonary disease.
Our study has some limitations. The absence 
of patients classified as having severe disease 
by the Shwachman-Kulczycki score and the 
number of participants in the CF group might 
explain the poor correlation between the clinical 
variables and the 6MWD.
In the present study, we demonstrated, by 
comparison with a control group, that functional 
capacity is impaired in patients with cystic 
fibrosis. Because there is no consensus regarding 
which published equations should be used for 
predicting normal values for the 6MWD in 
children and adolescents, the limitations of the 
present study, as well as those of other studies in 
the literature, might be overcome in multicenter 
studies, involving large samples and varying 
degrees of cystic fibrosis severity. We found that 
functional performance on the 6MWT was poorer 
among the cystic fibrosis patients than among 
the healthy controls in the same age bracket. We 
also found immediate repetition of the test to be 
unadvisable. The 6MWD correlated with weight, 
height, and percentage of predicted FEV1 in the 
CF group, and we developed a cystic fibrosis-
specific equation to predict 6MWD.
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